DHR

$218.85+1.36%Real quote · delayedLife sciences

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $24.6B · latest quarter up 5.5% YoY · profitable (FY net income $3.6B) · short activity within its normal range.

FY revenue

$24.6B

2025-12

Latest Q YoY

+5.5%

Gross margin

59.1%

FY net income

$3.6B

Diluted EPS

$5.07

Short volume

41.3%

20d avg 41.2% · normal

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
2026-03-26passive (13G)VANGUARD GROUP INC

🎯 Market expectations

Expectation reliability High · 76/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$1.96Estimate range $1.91 ~ $2.10 · 9 analystsRevisions (4w):↑2↓3

History: actual vs consensusavg +5.7%

Jun 2026$1.94 vs $1.84+5.43%
Mar 2026$2.06 vs $1.94+6.19%
Dec 2025$2.23 vs $2.22+0.45%
Sep 2025$1.89 vs $1.71+10.53%

This company habitually beats by +5.7% — the next report has to clear that bar to count as good news. Analysts cut estimates 3× in 4 weeks.

Analyst estimates, not our forecast · not investment advice

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction

● green = hit● red = miss● gray = pending (too recent to judge)▲bull ▼bear▂ volume

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.